Pathstone Family Office’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $3.45M | Buy |
65,263
+26,296
| +67% | +$1.38M | 0.03% | 348 |
|
|
2023
Q2 | $2.18M | Sell |
38,967
-2,897
| -7% | -$151K | 0.03% | 304 |
|
|
2023
Q1 | $2.08M | Sell |
41,864
-23,366
| -36% | -$1.1M | 0.03% | 282 |
|
|
2022
Q4 | $1.5M | Buy |
65,230
+28,060
| +75% | +$1.22M | 0.03% | 352 |
|
|
2022
Q3 | $1.44M | Buy |
37,170
+15,161
| +69% | +$608K | 0.03% | 304 |
|
|
2022
Q2 | $820K | Sell |
22,009
-3,027
| -12% | -$123K | 0.02% | 400 |
|
|
2022
Q1 | $1.11M | Buy |
25,036
+10,552
| +73% | +$457K | 0.03% | 305 |
|
|
2021
Q4 | $616K | Sell |
14,484
-425
| -3% | -$17.9K | 0.02% | 473 |
|
|
2021
Q3 | $647K | Buy |
14,909
+1,137
| +8% | +$50.3K | 0.02% | 421 |
|
|
2021
Q2 | $589K | Buy |
13,772
+1,397
| +11% | +$58.8K | 0.02% | 410 |
|
|
2021
Q1 | $478K | Buy |
12,375
+1,316
| +12% | +$49.8K | 0.02% | 350 |
|
|
2020
Q4 | $398K | Buy |
11,059
+968
| +10% | +$34.9K | 0.02% | 196 |
|
|
2020
Q3 | $385K | Hold |
10,091
| – | – | 0.04% | 138 |
|
|
2020
Q2 | $354K | Hold |
10,091
| – | – | 0.04% | 125 |
|
|
2020
Q1 | $329K | Sell |
10,091
-80
| -0.8% | -$3.13K | 0.05% | 128 |
|
|
2019
Q4 | $460K | Buy |
10,171
+80
| +0.8% | +$3.35K | 0.05% | 106 |
|
|
2019
Q3 | $411K | Sell |
10,091
-5,000
| -33% | -$212K | 0.05% | 107 |
|
|
2019
Q2 | $648K | Buy |
15,091
+5,000
| +50% | +$192K | 0.08% | 112 |
|
|
2019
Q1 | $387K | Buy |
10,091
+91
| +0.9% | +$3.48K | 0.05% | 129 |
|
|
2018
Q4 | $353K | Hold |
10,000
| – | – | 0.1% | 63 |
|
|
2018
Q3 | $385K | Hold |
10,000
| – | – | 0.12% | 42 |
|
|
2018
Q2 | $327K | Hold |
10,000
| – | – | 0.24% | 36 |
|
|
2018
Q1 | $273K | Hold |
10,000
| – | – | 0.15% | 44 |
|
|
2017
Q4 | $248K | Buy |
+10,000
| New | +$276K | 0.14% | 31 |
|
|
2017
Q2 | – | Sell |
-68
| Closed | -$2K | – | 416 |
|
|
2017
Q1 | $2K | Buy |
+68
| New | +$1.65K | ﹤0.01% | 370 |
|
|
2014
Q4 | – | Sell |
-125
| Closed | -$1K | – | 130 |
|
|
2014
Q3 | $1K | Buy |
+125
| New | +$1.57K | ﹤0.01% | 304 |
|
|
2014
Q2 | – | Sell |
-72
| Closed | -$1K | – | 138 |
|
|
2014
Q1 | $1K | Buy |
+72
| New | +$945 | ﹤0.01% | 168 |
|
|
2013
Q4 | – | Sell |
-865
| Closed | -$11K | – | 221 |
|
|
2013
Q3 | $11K | Buy |
+865
| New | +$9.36K | 0.05% | 172 |
|
Other funds holding BSX
Pathstone Family Office's BSX Position: Q3 2023 in Review
Pathstone Family Office increased its Boston Scientific (BSX) stake by 67% in Q3 2023, buying an estimated $1.38M and bringing the position to 65,263 shares worth $3.45M. The position accounts for 0.03% of the portfolio, ranked #348.
Pathstone Family Office first reported a position in BSX in Q3 2013 and has held it in 28 quarters since. 1,057 funds tracked by Wall St. Rank hold BSX as of Q3 2023.
- Pathstone Family Office held 65,263 shares of Boston Scientific worth $3.45M as of Q3 2023.
- Pathstone Family Office bought 26,296 Boston Scientific shares in Q3 2023, an estimated $1.38M.
- Boston Scientific made up 0.03% of Pathstone Family Office's portfolio in Q3 2023, its #348 holding.
- Pathstone Family Office first reported a position in Boston Scientific in Q3 2013 and has held it in 28 quarters since.
- 1,057 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2023.
Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.